The Effect of Correction of Metabolic Acidosis in CKD on Intrarenal RAS Activity

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

45 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-09-30

Study Completion Date

2018-12-27

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study evaluates the effect of oral sodium bicarbonate treatment on the intrarenal renin-angiotensin-system in adult patients with a metabolic acidosis and chronic kidney disease. This treatment is compared to sodium chloride treatment, which serves as control for increased sodium-intake and no treatment, which serves as time-control.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Sodium Bicarbonate in Intra-dialytic Hypertension in Chronic Hemodialysis Patients

NCT07231900

Hypertension in Dialysis Patients

NOT_YET_RECRUITING PHASE2/PHASE3

Bicarbonate Administration in CKD

NCT02915601

Chronic Kidney Disease Metabolic Acidosis

COMPLETED NA

Correction of Metabolic Acidosis in End Stage Renal Disease (ESRD)

NCT01640119

Metabolic Acidosis

UNKNOWN PHASE3

Explorative Study to Investigate the Acid-base Response to Sodium and Potassium Salts in Patients With Chronic Kidney Disease.

NCT06237712

Metabolic Acidosis CKD Electrolyte and Fluid Balance Conditions

ACTIVE_NOT_RECRUITING NA

Bicarbonate Administration and Cognitive Function in Midlife and Older Adults With CKD

NCT04600323

Metabolic Acidosis Chronic Kidney Disease Cognitive Dysfunction

COMPLETED EARLY_PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In chronic kidney disease (CKD), as glomerular filtration rate decreases, excretion of hydrogen ions fails, leading to progressive metabolic acidosis (arterial pH \< 7.35 and a serum bicarbonate concentration \< 22 meq/L). Metabolic acidosis enhances further progression of CKD. It is known that the intrarenal renin-angiotensin system (RAS) is stimulated during metabolic acidosis, but it's specific role in the renal response on changes in the acid-base balance is unknown. Correction of metabolic acidosis by administration of bicarbonate is a common intervention in patients with metabolic acidosis due to chronic kidney disease. It is proven to slow down progression of CKD. There is no knowledge on the effect this therapy has on the intrarenal RAS. Since acidosis does not change serum renin levels, and bicarbonate therapy has no effect on blood pressure, it seems to have no effect on the systemic RAS. The investigators hypothesize that bicarbonate therapy diminishes intrarenal RAS activity without affecting the systemic RAS.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Kidney Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Sodium bicarbonate

Oral sodium bicarbonate tablets three times daily 1000mg

Group Type EXPERIMENTAL

Sodium bicarbonate

Intervention Type DIETARY_SUPPLEMENT

Sodium chloride

Oral sodium chloride capsules two times daily 1000mg

Group Type ACTIVE_COMPARATOR

Sodium chloride

Intervention Type DIETARY_SUPPLEMENT

No treatment

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Sodium bicarbonate

Intervention Type DIETARY_SUPPLEMENT

Sodium chloride

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* male or female adult (≥18 years)
* chronic kidney disease stage 4, i.e. estimated glomerular filtration rate (MDRD) 15-30 ml/min
* plasma bicarbonate concentration of 15-24 meq/L

Exclusion Criteria

* bicarbonate level \>24 meq/L or \<15 meq/L, the latter because in that case it seems highly recommended to start sodium bicarbonate suppletion and not to postpone this
* sodium bicarbonate use in the 1 month preceding the study
* heart failure
* liver cirrhosis
* blood pressure \>140/90 mmHg despite the use of 3 different antihypertensives
* a kidney transplant in situ
* a history of nonadherence to medication
* use of calcineurin inhibitors (these immunosuppressive drugs are known to induce metabolic acidosis and influence electrolytes and acid-base balance)

Minimum Eligible Age

18 Years

Maximum Eligible Age

100 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No